PMID: 2120134Oct 15, 1990Paper

Induction of macrophage procoagulant expression by cisplatin, daunorubicin and doxorubicin

International Journal of Cancer. Journal International Du Cancer
H R Wheeler, C L Geczy

Abstract

Cisplatin, doxorubicin and daunorubicin (drugs which intercalate with DNA) influenced the membrane-bound procoagulant potential of murine thioglycollate-induced peritoneal exudate (TG-PEC) macrophages and the monocytoid cell line WEHI 265, whereas the antimetabolites 5-fluorouracil and methotrexate had no effect. Enhanced procoagulant was not caused by non-specific toxicity of these agents. Cisplatin directly increased the procoagulant expressed on WEHI 265 cells, whereas MPCA on TG-PEC was enhanced only when cisplatin was combined with a second stimulant, either bacterial lipopolysaccharide (LPS) or interferon (IFN gamma). WEHI 265 cells failed to respond to the anthracycline drugs, either alone or in combination with LPS, whereas they enhanced the IFN gamma response. Doxorubicin and daunorubicin increased the LPS response of TG-PEC by approximately 4-fold and the IFN gamma response by approximately 10-fold. Pulsing experiments suggested that the anthracyclines enhanced procoagulant expression by a mechanism different from cisplatin. Daunorubicin primed TG-PEC within 4 hr to respond to low levels of LPS, whereas either LPS or cisplatin primed these cells to respond to cisplatin or LPS respectively. Furthermore, the procoagulan...Continue Reading

References

Oct 16, 1978·Biochemical and Biophysical Research Communications·T R TrittonA C Sartorelli
Jun 1, 1989·Molecular and Cellular Biology·S A GregoryT S Edgington
Oct 1, 1989·Atherosclerosis·P G TippingS R Holdsworth
Apr 1, 1989·Proceedings of the National Academy of Sciences of the United States of America·J N WilcoxD Gordon
Oct 1, 1988·Seminars in Thrombosis and Hemostasis·J Lisiewicz
Jun 1, 1988·Journal of Interferon Research·D A EppsteinC G Kurahara
Jan 1, 1988·Experimental Cell Biology·S M Singh, A Sodhi
Apr 1, 1987·Immunology and Cell Biology·J Ryan, C Geczy
Feb 18, 1988·The New England Journal of Medicine·M N LevineS De Pauw
Jan 1, 1987·International Journal of Immunopharmacology·P Gupta, A Sodhi
Sep 1, 1986·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·D C DollJ W Yarbro
Jan 1, 1986·International Journal of Immunopharmacology·A Sodhi, S M Singh
Nov 1, 1985·American Journal of Hematology·E FibachE A Rachmilewitz
Jan 1, 1984·Annual Review of Immunology·D O Adams, T A Hamilton
Jan 1, 1984·Haemostasis·J W Shands
Jan 1, 1984·Haemostasis·R T DeanB C Rossi
Jan 1, 1984·Haemostasis·T L JansonH Prydz
Jan 1, 1982·Immunological Reviews·M J EhrkeE Mihich
Feb 1, 1983·British Journal of Haematology·T LybergK Nilsson
Jun 1, 1981·The Journal of Clinical Investigation·S G Gordon, B A Cross

❮ Previous
Next ❯

Citations

Aug 1, 1992·British Journal of Haematology·J WalshC L Geczy
Oct 1, 2011·Nanomedicine·Marina A DobrovolskaiaScott E McNeil
Jan 8, 2016·Toxicology and Applied Pharmacology·Marina A DobrovolskaiaAnna A Shvedova
Mar 6, 2004·Journal of Thrombosis and Haemostasis : JTH·V KaushalP Mehta
Feb 12, 2021·Arteriosclerosis, Thrombosis, and Vascular Biology·Steven P GroverNigel Mackman

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood Clotting Disorders

Thrombophilia includes conditions with increased tendency for excessive blood clotting. Blood clotting occurs when the body has insufficient amounts of specialized proteins that make blood clot and stop bleeding. Here is the latest research on blood clotting disorders.